The proteomics research market accounted for $1.8 billion in 2012, 43% of the total proteomics market, and is projected to grow at a compound annual growth rate (CAGR) of 9.7% to reach nearly $2.9 billion in 2017, accounting for 32.5% of the total market.
Online PR News – 08-June-2013 – Wellesley MA – WELLESLEY, Mass. – The proteomics research market accounted for $1.8 billion in 2012, 43% of the total proteomics market, and is projected to grow at a compound annual growth rate (CAGR) of 9.7% to reach nearly $2.9 billion in 2017, accounting for 32.5% of the total market. The research market consists of academic entities, research institutes and government laboratories.
The research market has been the main focus of proteomics products, which has resulted in strong growth. The market has been shifting toward applied end markets, including drug discovery and development, diagnostics, and applied laboratories. This trend is expected to continue as the industry moves toward more applied applications of proteomics. Research institutions, however, are expected to remain the focus of innovative technologies in the two key proteomics technologies: mass spectrometry and biochips.
The diagnostics market is the highest growth end-user market for proteomics. It reached $246.1 million in 2012; it is continuing to grow at a strong CAGR of 43.5% and is expected to reach a value of nearly $1.5 billion in 2017. Key growth drivers for the diagnostics market include a modest but growing pipeline of proteomics-based tests; increasing acceptance of multiplexed diagnostics tests; a high discovery rate of protein biomarkers; and a strong need for automated, rapid, and less-costly tests.
The proteomics industry is extremely diverse, with intense competition in many market segments. The industry contains a range of lifecycle technologies, which makes it attractive to companies that can innovate in early or emerging market segments. Proteomics technologies have proven to be indispensable tools within the life-science industries, and they will continue to provide opportunities for innovators in the future.
Exciting developments likely to affect the future of proteomics include platforms with both genomic and proteomic content, the use of next-generation sequencing platforms for proteomics analysis, the development of novel protein and peptide affinity chemistries, and label-free methods.
The two key proteomic technologies – mass spectrometry and biochips – are benefiting from an explosion of new proteomics content from the large-scale genomic and proteomic initiatives. This proteomic content is driving the discovery of new biomarkers that are important in disease processes.
At the same time, improvements in technologies are driving proteomic applications. Increasing miniaturization and integration of biochip devices, as well as improvement in mass spectrometry workflow and instruments, are creating new applications in drug discovery and development and diagnostics.
The scope of the BCC Research report, Proteomics: Technolgies and Global Markets (BIO034C), covers mass spectrometry (MS) instruments, consumables, workflow products, planar arrays, bead arrays, and lab-on-a-chip (LOAC). It also covers the research, drug discovery and development, diagnostics, and applied end-user market segments. The main geographical markets – North America, Europe, Japan, and Rest of the World (ROW) – are included.
The MS market is covered by instrument type, MS consumables, product type, and end-user markets. The biochip market is covered by biochip type and the-end user market for each type. The diagnostics market is covered in some detail, including by major platform (i.e., MS, biochips), by disease type, and for cancer by indication.
This report provides the current market sizes for these segments, as well as their forecast growth through 2017.